Comparative Analysis of Methods to Measure Aerosols Generated by a Vibrating Mesh Nebulizer
Authors:
- 1 September 2007
- journal article
- research article
- Published by SAGE Publications in Journal of Aerosol Medicine
- Vol. 20 (3) , 310-319
Abstract
Different approaches have been employed for in vitro assessment of the aerosol particle size generated by inhalation devices. In this study, aerosols from the Omron MicroAir vibrating mesh (VM) nebulizer were measured by cascade impaction (CI) using the MSP Next Generation Pharmaceutical Impactor (NGI), the ThermoAndersen Cascade Impactor (ACI), and by time-of-flight (TOF) analysis with the TSI 3321 Aerodynamic Particle Sizer Spectrometer (APS). The VM nebulizer was evaluated with sodium fluoride (NaF; 2.5%) and with generic albuterol (0.083%). Aerosol particle size (MMAD), respirable fractions (RF < 5 microm), and fine particle fractions (FPF < 3.3 microm) were determined with each method at room temperature (RT) and 4 degrees C using 50% average relative humidity. By NGI at either RT or 4 degrees C, aerosol particle sizes were similar for both NaF and albuterol (4.3-4.5 microm MMAD) with 55-61% RF and 27-43% FPF. With ACI, the distribution of particles at RT was similar except at the extremes of the dispersion and the MMAD was smaller (3.3 microm MMAD; p = 0.03). At 4 degrees C, particle sizes determined by ACI results were similar to the NGI (MMAD 4.1 microm; p > 0.05). TOF analysis by APS with albuterol gave significantly larger calculated MMAD (cMMAD) than either CI method (7.2 microm; p < 0.001). TOF measurements of nebulized albuterol at RT and 4 degrees C were equivalent. In summary, the results of VM nebulized NaF and albuterol were more consistent and generally equivalent when determined by NGI (at RT and 4 degrees C) and ACI analysis (at 4 degrees C). In contrast, aerosol particle sizes measured by TOF in the APS at both RT and 4 degrees C were larger than results obtained by CI. Differences in aerosol particle distribution obtained by different analysis methods should be considered while evaluating the in vitro performance of VM nebulizers.Keywords
This publication has 18 references indexed in Scilit:
- Device Selection and Outcomes of Aerosol Therapy: Evidence-Based GuidelinesChest, 2005
- Next Generation Pharmaceutical Impactor: A New Impactor for Pharmaceutical Inhaler Testing. Part III. Extension of Archival Calibration to 15 L/minJournal of Aerosol Medicine, 2004
- Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometerAAPS PharmSciTech, 2003
- Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part II: Archival CalibrationJournal of Aerosol Medicine, 2003
- Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: DesignJournal of Aerosol Medicine, 2003
- Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003
- Evaluation of a New Aerodynamic Particle Sizer ® Spectrometer for Size Distribution Measurements of Solution Metered Dose InhalersJournal of Aerosol Medicine, 2003
- European Respiratory Society Guidelines on the use of nebulizersEuropean Respiratory Journal, 2001
- Validation of Laser Diffraction Method as a Substitute for Cascade Impaction in the European Project for a Nebulizer StandardJournal of Aerosol Medicine, 2001
- Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an anderson impactorJournal of Aerosol Science, 1999